xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06004128</url>
    </required_header>
    <id_info>
      <org_study_id>VYD222-EA-001</org_study_id>
      <nct_id>NCT06004128</nct_id>
    </id_info>
    <brief_title>Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments</brief_title>
    <official_title>Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Invivyd, Inc.</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>In Expanded Access, treating physicians are the Sponsors</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Invivyd, Inc.</source>
    <brief_summary>
      <textblock>
        Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for&#xD;
        patients with symptomatic COVID-19 refractory to other treatments.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>No longer available</overall_status>
    <study_type>Expanded Access</study_type>
    <has_expanded_access>No</has_expanded_access>
    <expanded_access_info>
      <expanded_access_type_individual>Yes</expanded_access_type_individual>
    </expanded_access_info>
    <condition>COVID-19</condition>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>VYD222</intervention_name>
      <description>Monoclonal antibody</description>
    </intervention>
    <eligibility>
      <gender>All</gender>
      <minimum_age>N/A</minimum_age>
      <maximum_age>N/A</maximum_age>
    </eligibility>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 18, 2023</study_first_submitted>
    <study_first_submitted_qc>August 18, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 22, 2023</study_first_posted>
    <last_update_submitted>August 18, 2023</last_update_submitted>
    <last_update_submitted_qc>August 18, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 22, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>COVID-19</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06004128
  org study id: VYD222-EA-001
  nct id: NCT06004128
  lead sponsor: 
  collaborator: 
  Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for
        patients with symptomatic COVID-19 refractory to other treatments.
  expanded access type individual: Yes
  intervention type: Drug
  intervention name: VYD222
  description: Monoclonal antibody
  gender: All
  minimum age: N/A
  maximum age: N/A
  responsible party type: Sponsor
  mesh term: COVID-19